20:07 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample, cell culture and mouse studies suggest activating AMPK could help treat pulmonary fibrosis. In lung tissue samples from idiopathic pulmonary fibrosis (IPF) patients, fibroblast levels of activated AMPK were lower...
20:00 , Apr 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver disease Mouse studies suggest AMPK activators could help treat non-alcoholic fatty liver disease (NAFLD). In mice, liver-specific expression of an overactive human mutant AMPK decreased glucose production and fatty acid synthesis compared with...
19:00 , Mar 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Myotonic dystrophy type 1 (DM1) Patient sample and mouse studies suggest activating AMPK or inhibiting mTORC1 could help treat DM1. In muscle tissue samples from patients and a genetic mouse model of DM1, levels...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

O304: Phase IIa started

Betagenon began the double-blind, placebo-controlled, Swedish Phase IIa TELLUS trial to evaluate 1,000 mg oral O304 once daily for 28 days in 66 patients. Betagenon AB , Stockholm, Sweden   Product: O304   Business: Endocrine/Metabolic...
08:00 , Feb 16, 2012 |  BC Innovations  |  Targets & Mechanisms

Still un-sirtuin

Researchers at the NIH have proposed a new mechanism to explain the beneficial metabolic effects of resveratrol, a polyphenol compound from red wine thought by many to act primarily on sirtuin 1 . The NIH...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Clinical News

Betagenon preclinical data

In obese diabetic mice, oral O304 significantly increased exercise endurance and promoted blood glucose disposal. In rats, the AMP-activated protein kinase (AMPK) activator stimulated the generation of active brown fat cells. Betagenon AB , Stockholm,...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Company News

Antisoma, Betagenon deal

Betagenon granted Antisoma exclusive, worldwide rights to develop and market undisclosed preclinical AMP-activated protein kinase (AMPK) activators to treat cancer. Betagenon will receive an undisclosed upfront payment and research funding and will be eligible for...
07:00 , Apr 21, 2008 |  BioCentury  |  Finance

Ebb & Flow

Less than a month after completing its acquisition of cancer and infectious disease company Celldex in a stock deal for about $75 million, Avant (NASDAQ:AVAN) has received cash covering more than half of the purchase...
00:42 , Apr 15, 2008 |  BC Extra  |  Company News

Antisoma, Betagenon in cancer deal

Betagenon (Stockholm, Sweden) granted Antisoma (LSE:ASM) exclusive, worldwide rights to develop and market its undisclosed preclinical AMP-activated protein kinase (AMPK) activators to treat cancer. Betagenon will receive an undisclosed upfront payment and research funding and...